MDMA-assisted therapy for PTSD (2021-2026)
A living meta-analysis of six randomized trials covering 286 participants found MDMA-assisted therapy roughly doubled remission odds versus controls. Reported remission reached 68% at one year of follow-up in some cohorts.
The FDA granted expanded access, letting treatment-resistant patients receive the therapy before full approval.
MDMA remains a Schedule 1 drug, and the therapy still lacks final FDA approval.
It is the other leading non-drug PTSD treatment with remission rates near 68%, showing both the promise and the regulatory friction such therapies face.
